Relationship between a novel polymorphism of hepatic lipase gene and coronary artery disease

Zhi-Guang Su1, Si-Zhong Zhang, Yi-Ping Hou

  • 1Department of Medical Genetics, West China Hospital, Sichuan University, Chengdu 610041, China. szzhang@mswcums.com

Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao Acta Biochimica Et Biophysica Sinica
|November 6, 2002
PubMed

Insights

A novel genetic variation in the hepatic lipase (HL) gene promoter was identified in Chinese patients with coronary artery disease (CAD). This variation is linked to higher HDL-cholesterol levels and an increased risk of CAD.

Area of Science:

  • Genetics
  • Cardiovascular Disease
  • Biochemistry

Background:

  • Hepatic lipase (HL) is crucial for lipoprotein metabolism, influencing high-density lipoprotein (HDL) and low-density lipoprotein (LDL) levels.
  • HL activity is associated with coronary artery disease (CAD) susceptibility.
  • Genetic variations in the HL gene may impact CAD risk, but data in Chinese populations is limited.

Purpose of the Study:

  • To investigate single nucleotide polymorphisms (SNPs) in the HL gene in Chinese individuals with and without CAD.
  • To determine the association of identified HL gene SNPs with CAD risk and HDL-cholesterol levels.

Main Methods:

  • Genomic DNA was extracted from Chinese CAD patients and controls.
  • The promoter and exons of the HL gene were amplified using PCR.
  • PCR products were analyzed by denaturing high-performance liquid chromatography (DHPLC) and DNA sequencing.

Main Results:

  • A novel SNP, -2T>C, was discovered in the promoter region of the HL gene.
  • The -2C allele was significantly more prevalent in CAD patients (57.9%) compared to controls (42.7%).
  • Carriage of the -2C allele was associated with a 1.58-fold increased risk of CAD and higher HDL-cholesterol levels in homozygous carriers.

Conclusions:

  • The novel -2T>C SNP in the HL gene promoter is associated with altered HDL-cholesterol concentrations.
  • This genetic variation may contribute to the risk of coronary artery disease in the Chinese population.

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...